AEGiS-GMHC: Treatment Briefs: New Clinical Trials

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Treatment Briefs: New Clinical Trials

Gay Men's Health Crisis "Treatment Issues"; Vol. 8, No. 7 - August 1994
David Gold

SUNY at Stony Brook is now enrolling participants for three studies involving the new Merck protease inhibitor. One is a dose escalation study for which previous AZT experience is irrelevant. The other two involve combinations of the Merck drug and either AZT or AZT plus ddI and require participants to have had little past experience with AZT. Call 516/444-1658.

An eight-week study of a soluble Interleukin-1 (IL-1) receptor in HIV-positive individuals with less than 300 CD4 cells is underway at Memorial Sloan Kettering in New York City. IL-1, a cytokine, is overproduced in people with HIV and is believed to increase HIV replication and possibly stimulate KS cell growth. The receptor, it is hoped, will bind to circulating IL-1. Call 212/639-7161.

A study of acitretin, a retinoid, in the treatment of psoriasis in HIV- positive individuals is underway at Beth Israel Hospital in New York. Call Leslie Borow at 212/420-3000.

Rockefeller University is studying interleukin-2 (IL-2) as a treatment for HIV. Participants must have 300 to 500 CD4 cells and be on AZT, ddI or ddC. Call Dr. Tang at 212/327-7795.

The UCLA Center for AIDS Research is studying the safety of a single dose of recombinant human IL-12 in HIV-positive individuals with CD4 counts between 100 and 500. Call 310/206-6414.

Copyright (c) 1994 - GMHC Treatment Issues. Noncommercial reproduction encouraged. Distributed by AEGIS, your online gateway to a world of people, knowledge, and resources. Direct Dial: v.34+: 714.248.2836; v.120/ISDN: 714.248.0433 Internet: telnet:aegis.com www: www.aegis.com
940810
GM080711

Copyright © 1994 - Treatment Issues. Reproduced with permission. Treatment Issues is published twelve times yearly by GMHC, Inc. All rights reserved. Noncommercial reproduction is encouraged. Subscription lists are kept confidential. GMHC Treatment Issues, The Tisch Building, 119 West 24th Street, New York, NY 10011 fredg@gmhc.org http://www.gmhc.org

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .